KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kalaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.91−0.09 (-4.50%)
Close on Oct 19, 2026
- Market cap
- $45.45M
- P/E (TTM)
- –
- Dividend yield
- –
Kalaris Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Market Cap | $45.47M | $164.85M |
| Enterprise Value | -$48.03M | $87.06M |
| PB Ratio | 0.79 | 2.03 |
| P/TBV Ratio | 0.79 | 2.31 |
Income (trailing twelve months)
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$47.76M | -$21.44M |
| Net Income | -$44.26M | -$22.46M |
| EBITDA | -$47.76M | -$16.91M |
Returns
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -79.9% | -53.1% |
| Return on Assets (ROA) | -46.0% | -41.0% |
| Return on Capital Employed (ROCE) | -52.6% | -37.8% |
Balance sheet
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $93.50M | $62.42M |
| Net Cash (Debt) | $93.50M | $15.68M |
| Net Cash Per Share | $3.93 | $0.66 |
| Equity (Book Value) | $57.67M | $48.79M |
| Book Value Per Share | $2.42 | $1.36 |
| Tangible Book Value | $57.67M | $23.06M |
| Working Capital | $87.18M | $75.77M |
Financial position
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.98 | 3.30 |
| Quick Ratio | 10.70 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$41.02M | -$12.35M |
Efficiency
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.21M | -$703.34K |
| Employee Count | 20 | 74 |
Dividends and yields
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -97.4% | -22.7% |
Shares
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 23,805,000 | 58,179,650 |
| Shares Change (YoY) | 236.5% | 11.1% |
| Shares Change (QoQ) | 3.53% | 0.54% |
| Shares Held by Institutions | 75.8% | 59.4% |
Scores
| Measure | Kalaris Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -2.45 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Kalaris Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.